Galmed Pharmaceuticals
Next Generation of Metabolic and Inflammatory Therapeutics
Startup Public Health Tech & Life Sciences Est. 2000
🌐 WebsiteLinkedInTwitter
Total Raised
$150.3M
Public
Last Round
$7M
5 rounds
Team
6
1-10 employees
Confidence
91/100
News
68
articles
Patents
1
About
Galmed Pharmaceuticals is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. The company is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and recently initiated a first in human study.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
Biologicals
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business Model
B2B
Tags
metabolic-diseasedrug-discoverypharmaceuticalsmicrobiomebiopharmaceuticaloral-drugscrohn's-diseasediabetespharma-companiesinflammatory-diseases
Funding & Events
Mar 2014
Exit Undisclosed
Jun 2018
Exit Undisclosed
Jul 2023
Exit Undisclosed
Jan 2018
Exit Undisclosed
Feb 2021
Exit Undisclosed
News (68)
Aug 28, 2025 · finance.yahoo.com
growth-positive
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Product StagePartnersInvestment
Aug 28, 2025 · finance.yahoo.com
growth-positive
Galmed Pharmaceuticals: Q2 Earnings Snapshot
Aug 28, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases...
PartnersInvestment
Aug 25, 2025 · finance.yahoo.com
growth-positive
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value
InvestmentPartners
Aug 25, 2025 · www.prnewswire.com
growth-positive
An amendment to the Company's Articles of Association to increase the authorized share capital from 50,000,000 ordinary shares to 900,000,000 ordinary shares...
InvestmentPartners
May 27, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of liver,...
Product StagePartners
May 27, 2025 · finance.yahoo.com
growth-positive
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH
Product StagePartners
May 22, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases...
Product StageInvestmentPartners
May 22, 2025 · finance.yahoo.com
growth-negative
Galmed Pharmaceuticals: Q1 Earnings Snapshot
May 22, 2025 · finance.yahoo.com
growth-positive
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Product StageInvestmentPartners
May 13, 2025 · finance.yahoo.com
growth-positive
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models
Product Stage
May 13, 2025 · www.prnewswire.com
growth-positive
Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC) Aramchol treatment...
Product Stage
May 10, 2025 · finance.yahoo.com
growth-positive
Biotech Alert: Searches spiking for these stocks today
Product StageCustomers
May 6, 2025 · finance.yahoo.com
growth-positive
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models
Product StagePartners
May 1, 2025 · finance.yahoo.com
growth-positive
Biotech Alert: Searches spiking for these stocks today
Product StageFDA approved/pending approval
Apr 28, 2025 · finance.yahoo.com
growth-positive
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation
PartnersProduct Stage
Apr 28, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases...
PartnersProduct Stage
Apr 17, 2025 · finance.yahoo.com
growth-positive
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers
PartnersProduct Stage
Apr 15, 2025 · finance.yahoo.com
growth-positive
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor
Product StagePartners
Apr 10, 2025 · finance.yahoo.com
growth-positive
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor
Product StageFDA approved/pending approval
+ 48 more articles
Details
Product Stage
Clinical Trial
Employees
1-10
Exact Count
10
District
Center District
Founded
2000
Registrar
514953512
Crunchbase
galmed-pharmaceuticals
Locations
16 Tiomkin Street, Tel Aviv
Links
Website
galmedpharma.com
LinkedIn
Profile
Twitter
Profile
Facebook
Page
Admin
Last Update
Aug 28, 2025
Verified by
Sharon Shapira
Missing
funding rounds, markets, not claimed
Team (6)
Allen Baharaff
President & CEO
Guy Nehemya
COO
Yohai Stenzler
Chief Accounting Officer
Tali Gorfine
Chief Medical Officer
Liat Hayardeny
Chief Scientific Officer
Joseph Kaspi
Senior CMC Director
Internal
Created by
Sharon Shapira (shapira.sharon2@gmail.com)
Created
2014-12-02T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)
Status
Public on NASDAQ on Mar, 2014<br>
Finder · Galmed Pharmaceuticals · 2026